Explore the Agenda

7:30 am Check-in

Check in & Light Refreshments

8:25 am Chair’s Opening Remarks

Leveraging Experimental Data to Enable Shorter Design & Engineering Timelines For Deeper Biological Understanding & More Informed Drug Design Decisions

8:30 am Harnessing Artificial Intelligence & Cryo-EM to Accelerate Structure-Based Drug Discovery

Director, Head of Structural Biology, Pfizer
  • Leveraging machine learning–guided construct optimization to improve protein expression, stability, and cryo-EM suitability
  • Accelerating structural determination of dynamic and difficult targets such as membrane proteins and large complexes
  • Combining AI-assisted protein engineering with cryo-EM structural analysis to generate actionable SBDD insights

9:00 am From Microscopes to Medicines: Trends & Opportunities for CryoEM at Scale in Discovery & Development

Sr. Director/General Manager, Pharma, Thermo Fisher Scientific Inc

Over the past decade, cryoEM has transformed structure-based drug design, unlocking new targets, enabling rational design of increasingly complex modalities and characterization of new delivery vehicles. Bolstered by new AI-powered capabilities for date ingestion at scale and in silico design, demand for structural data is increasing year on year. Here we will survey the current status of structural biology and discuss areas of innovation essential to keep pace with today’s acceleration pace of discovery.

9:30 am Aligning Construct Strategy, Stability & Biology for Modern Structure-Based Drug Design

Senior Scientist, Insitro
  • Designing construct strategies that maximize structural yield and biological fidelity
  • Balancing speed and exploration when screening multiple protein variants in parallel
  • Demonstrating why high expression yield alone is insufficient, and how prioritising functional competence and conformational relevance have prevented misleading ligand poses and downstream design errors
  • Delving into expression, production, solubilization, and stabilization strategies to overcome heterogeneity and preserve biologically relevant conformations

10:00 am Speed Networking & Morning Break

This informal session provides the perfect opportunity to connect with your industry colleagues, from structural biologists to medicinal and computational chemists, protein engineers, and drug discovery experts. Instigate useful introductions to build upon for the rest of the conference forming valuable connections.

11:00 am Bridging Structural Biology & Cell Biology: Designing Fusion Protein Therapeutics Using 3D Cell-Surface Models

  • Constructing three-dimensional structural models of the red blood cell surface to contextualize drug–target interactions beyond single protein structures
  • Using structural insight to design engineered fusion proteins that achieve tissue targeting while minimizing unintended crosslinking and side effects
  • Demonstrating how rational protein design, leveraging published cryo-EM structural data, can replace large discovery platforms, enabling small teams to develop novel biologics efficiently
  • Leveraging published cryo-EM structural data and integrative modelling to connect molecular structures with cell-level therapeutic mechanisms

Navigating the Reality of Modern Structural Biology Pipelines to Overcome Experimental Constraints & Improve Success Rates

11:30 am From Density to Decisions: Automated, Cloud-Native cryo-EM at Scale

PhD, Co-Founder & CEO, CryoCloud, CryoCloud
  • Removing the access and throughput bottlenecks: scalable on-demand processing and real-time Live Analysis to reduce turnaround times
  • From map to model: new algorithms and high-throughput workflows that raise resolution and confidence on dynamic and challenging targets
  • Enabling confident small-molecule decisions: unsupervised ligand localization, quantification and visualization to validate binding sites and turn data into actionable insights

12:00 pm Panel Discussion: The Reality of Cryo-EM Access, Bottlenecks & Future Directions

Associate Director, Structural Biology, Genesis Molecular AI
Sr Research Fellow, Abbvie
Scientist II, Relay Therapeutics
Associate Director & Structural Biology Lead, Vividion Therapeutics
  • Comparing access, cost, and timelines for large pharma versus biotechs, and when outsourcing or academic partnerships make more sense
  • Addressing challenges around data volume, selection, and cloud storage
  • How data processing, classification, and refinement workflows impact turnaround time and confidence in results
  • Current constraints including size limits, flexibility, heterogeneity, and challenges with smaller molecules or weak interactions
  • Emerging hardware, sample preparation strategies, and computational advances aimed at improving resolution, throughput, and applicability

12:45 pm Lunch Break & Networking

1:45 pm Building the Plane While Flying: Embedding Structural Biology in a Platform-Driven Discovery Model

Associate Director & Structural Biology Lead, Vividion Therapeutics
  • Operating in a platform-driven discovery model where programs launch before full mechanistic understanding is established
  • Using single-particle cryo-EM to resolve divergent mechanisms for distinct chemotypes binding the same pocket
  • Identifying alternative binding sites on well-studied targets to enable differentiated pharmacology

2:15 pm Advancing the Frontier of Cryo-EM Data Processing for Drug Discovery with CryoSPARC

CEO, Structura Biotechnology
  • Illustrate how the specially designed algorithmic and software innovations in CryoSPARC enable and accelerate cryo-EM structure determination for drug discovery pipelines
  • Demonstrate the state-of-the-art in fully automated cryo-EM processing that is being adopted in industry workflows today to produce higher quality results than manual processing with faster time-to-structure and reduced cost
  • Showcase how CryoSPARC serves as an evolving platform that keeps cryo-EM teams at the forefront of the field, unblocking structural insight for challenging drug targets

2:45 pm Evaluating Co-Folding Models Against Experimental & Clinical Reality

Head of Computation, AI Proteins
  • How co-folding models have been employed to guide early design choices and prioritization
  • Evaluating how predicting binding modes and interaction interfaces have aligned with functional assays, in vivo behaviour and translational readouts 
  • Reviewing where predicted interaction surfaces informed mechanism of action understanding, and where experimental structures were required to solve uncertainty

Building Reliable AI-Driven Discovery Workflows that Integrate Prediction, Data & Experimental Validation that Close the Gap Between Computational Models & Biological Reality

3:15 pm Closing the Loop Between Structural Biology & AI: Improving Nanobody Structure Prediction with Targeted Experimental Data

Structural Biology & Computational Design Scientist, Sanofi
  • Identifying low-confidence regions in AI-driven protein structure prediction models for nanobodies through computational analysis
  • Designing custom structural biology experiments to generate targeted training data that improves model accuracy
  • Showcasing how close collaboration between wet lab structural biology and AI teams can iteratively refine predictive models for biologics discovery

3:45 pm Accelerating Macrocyclic Lead Optimization: Integrating Computational Approaches with Structural Data

Principal Scientist, Optibrium
  • Applying a fast, template-free approach to macrocycle conformational search to increase lead optimization efficiency by 5-10X
  • Using structural data to constrain the conformational search and identify bioactive conformations
  • Modelling ligand strain accurately to reveal how small structural modifications can drive large changes in binding affinity

3:55 pm Afternoon Break & Poster Session

Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships 

while exploring the latest advancements in structure-based drug design. 

To register your poster submission, please contact info@hansonwade.com

4:15 pm Interactive Exchange: Aligning Computational Prediction with Experimental Reality

Head of Computational Chemistry, Monte Rosa Therapeutics

Following a series of perspectives from structural and computational experts, this interactive session will shift the focus from presentation to participation. Through structured, topic-led roundtable rotations, attendees will explore where predictive modelling delivers real value, where it falls short, and how experimental data quality influences model performance.

Participants will compare workflows, discuss bottlenecks in data generation and validation, and share practical insights on integrating modelling with structural and biophysical evidence to improve confidence in discovery decisions.

4:45 pm Panel Discussion: Combining AI Platform Technologies to Move from Structural Insight to Informed Drug Design Decisions

Director, Protein Design & Optimization, Tectonic Therapeutic
Head of Computational Chemistry, Monte Rosa Therapeutics
Structural Biology & Computational Design Scientist, Sanofi
Head of Computation, AI Proteins
  • Leveraging foundation models to navigate complex protein systems (multi-domain, membrane-embedded, inducedproximity targets) that exceed the limits of single-structure or single-model approaches
  • Combining AI-driven protein design with experimental structure generation to resolve ambiguity in binding modes, conformational states, and interaction interfaces
  • Closing the loop between AI predictions and wet-lab validation by continuously retraining models on construct performance, structural success, and functional readouts

5:30 pm Chair’s Closing Remarks

5:35 pm End Of Conference Day One

5:35 pm Drinks Reception